{"altmetric_id":14543916,"citation":{"altmetric_jid":"clinicaltrialsgov","authors":["NSABP Foundation Inc"],"first_seen_on":"2016-12-07T20:49:40+00:00","issns":[],"journal":"ClinicalTrials.gov","last_mentioned_on":1481140800,"links":["https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00382070"],"nct_id":"NCT00382070","pubdate":"2006-09-26T00:00:00+00:00","publisher":"ClinicalTrials.gov","title":"Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer","type":"clinical_trial_study_record"},"altmetric_score":{"score":7,"score_history":{"1y":7,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":7},"context_for_score":{"all":{"total_number_of_other_articles":7856296,"mean":6.655704591281,"rank":1087617,"this_scored_higher_than_pct":85,"this_scored_higher_than":6698059,"rank_type":"exact","sample_size":7856296,"percentile":85},"similar_age_3m":{"total_number_of_other_articles":250953,"mean":12.283018370046,"rank":52081,"this_scored_higher_than_pct":77,"this_scored_higher_than":195363,"rank_type":"exact","sample_size":250953,"percentile":77},"this_journal":{"total_number_of_other_articles":21469,"mean":10.218321688094,"rank":3508,"this_scored_higher_than_pct":75,"this_scored_higher_than":16169,"rank_type":"exact","sample_size":21469,"percentile":75},"similar_age_this_journal_3m":{"total_number_of_other_articles":756,"mean":9.5360874172185,"rank":89,"this_scored_higher_than_pct":85,"this_scored_higher_than":647,"rank_type":"exact","sample_size":756,"percentile":85}}},"demographics":[],"counts":{"total":{"posts_count":1},"news":{"unique_users_count":1,"unique_users":["oncology_nurse_advisor"],"posts_count":1}},"posts":{"news":[{"title":"Extended Treatment With Letrozole Fails to Improve DFS in HR+ Breast Cancer","url":"http:\/\/www.oncologynurseadvisor.com\/extended-treatment-with-letrozole-fails-to-improve-dfs\/article\/577727\/","license":"public","citation_ids":[14543916],"posted_on":"2016-12-07T20:00:00+00:00","summary":"December 07, 2016 Extended Treatment With Letrozole Fails to Improve DFS in HR+ Breast Cancer SAN ANTONIO \u2013 Extended treatment with letrozole for 5 years did not significantly improve disease-free survival in women with hormone receptor (HR)-positive\u2026","author":{"name":"Oncology Nurse Advisor ","url":"http:\/\/www.oncologynurseadvisor.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/276\/normal\/Screen_Shot_2014-11-20_at_11.19.42.png?1416482413"}}]}}